Ancobon
(flucytosine)Phase 3Small molecule
Ancobon is one of 3 small molecule programs targeting Talaromycosis. It is currently in Phase 3.
1
Indications
18
Total Trials
1
Active Trials
2
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Talaromycosis
#DrugCompanyPhaseTrials
1Liposomal Lurtotecan
GileadPhase 3
Ancobon
BBausch Health Americas, Inc.
Phase 3
Liposomal Amphotericin B
SSichuan Provincial People's Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cryptococcal Meningitis11 trials
A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000639·400 enrolled
Show 8 more trials
Dexamethasone in Cryptococcal Meningitis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000776·36 enrolled
Glioma2 trials
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
Completed·—·Phase 1·NCT02015819·16 enrolled
Metastatic Colorectal Cancer1 trial
2 more indications
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
ANCOBON
NDA NDA017001
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for flucytosine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBausch Health Americas, Inc.